| |
Study part I (1000 mg Glucophage) |
Study part II (500 mg Glucophage) |
| Patients, N |
28 |
28 |
| Age, y (SD) |
36.0 (10.2) |
37.2 (9.9) |
| Sex, n (%) |
|
|
| Female |
13 (46.4) |
15 (53.6) |
| Male |
15 (53.6) |
13 (46.4) |
| Body mass index, kg/m2 |
23.6 (2.6) |
22.9 (2.8) |
| Smoking status, n (%) |
|
|
| Never smoked |
14 (50.0) |
13 (46.4) |
| Ex-smoker |
9 (32.1) |
10 (35.7) |
| Smoker |
5 (17.9) |
5 (17.9) |
| Alcohol status |
|
|
| Non-drinker |
9 (32.1) |
5 (17.9) |
| Drinker − no interference* |
19 (67.9) |
23 (82.1) |
| Drinker – possible interference* |
0 (0.0) |
0 (0.0) |
*Interference with trial participation (subjects were not allowed to consume alcoholic
beverages from 7 days before drug administration until the end of the study) |
